| 產(chǎn)品名稱 | Foretinib - GSK 1363089 | Exel 2880 | XL 880 |
| 產(chǎn)品貨號(hào) | Axon 1582 CAS [849217-64-7] MF C34H34F2N4O6MW 632.65 Purity: 98% Soluble in DMSO Description An orally available inhibitor targeting c-MET (IC50: 0.4 nM) and VEGFR2 References Certificates Categories Extra info JP Eder et al. A Phase I Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Early Antitumor Activity of Foretinib. Clin. Cancer Res. 2010, 16(13),?3507. ? L Liu?et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009, 69(17), 6871-8.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology c-MET RTK class X; EC 2.7.10.1 c-MET and VEGFR2 tyrosine kinase inhibitor Chemical name N-(4-(7-(3-morpholinopropoxy)-6-methoxyquinolin-4-yloxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Parent CAS No. [849217-64-7] Order Size Unit Price Stock 5 mg €90.00 In Stock |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Foretinib - GSK 1363089 | Exel 2880 | XL 880Axon 1582 CAS [849217-64-7] MF C34H34F2N4O6
Description
An orally available inhibitor targeting c-MET (IC50: 0.4 nM) and VEGFR2
c-MET and VEGFR2 tyrosine kinase inhibitor
Chemical nameN-(4-(7-(3-morpholinopropoxy)-6-methoxyquinolin-4-yloxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Parent CAS No.[849217-64-7] |
| 產(chǎn)品資料 |
